PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 11:35:11 20/05/2024 pm IST | ||
| 12.57 EUR | -1.26% |
|
| Current month | -11.23% | ||
| 1 month | -23.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 12.57 | -1.26% |
| 17/24/17 | 12.73 | -0.08% |
| 16/24/16 | 12.74 | +5.03% |
| 15/24/15 | 12.13 | -7.97% |
| 14/24/14 | 13.18 | -0.83% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 11:35 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ9GKN |
| ISIN | DE000VQ9GKN4 |
| Date issued | 12/07/2021 |
| Strike | 365.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.12 € |
|---|---|
| Lowest since issue | 1.41 € |
| Spread | 0.16 € |
| Spread % | 1.26% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
231.6
USD
Average target price
285.9
USD
Spread / Average Target
+23.47%
- Stock Market
- Certificates
- Certificat